ESR1 and breast cancer: This is while the expression of the protein (in this case STS) identifies a cancer with a less aggressive phenotype, thus better survival (e.g., better survival in ERα positive breast cancer vs negative, e.g., Viale et al., 54 better survival in AR positive TNBC vs negative55 inhibition of that protein may cause growth arrest and thus be beneficial in the long term to patient outcomes.